McDevitt MR - Search Results

1

Alpha-particle emitting atomic generator (Actinium-225)-labeled trastuzumab (herceptin) targeting of breast cancer spheroids: efficacy versus HER2/neu expression.

Ballangrud AM, Yang WH, Palm S, Enmon R, Borchardt PE, Pellegrini VA, McDevitt MR, Scheinberg DA, Sgouros G. Ballangrud AM, et al. Among authors: mcdevitt mr. Clin Cancer Res. 2004 Jul 1;10(13):4489-97. doi: 10.1158/1078-0432.CCR-03-0800. Clin Cancer Res. 2004. PMID: 15240541

2

Radioimmunotherapy with alpha-emitting nuclides.

McDevitt MR, Sgouros G, Finn RD, Humm JL, Jurcic JG, Larson SM, Scheinberg DA. McDevitt MR, et al. Eur J Nucl Med. 1998 Sep;25(9):1341-51. doi: 10.1007/s002590050306. Eur J Nucl Med. 1998. PMID: 9724387 Review.

3

Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry.

Nikula TK, McDevitt MR, Finn RD, Wu C, Kozak RW, Garmestani K, Brechbiel MW, Curcio MJ, Pippin CG, Tiffany-Jones L, Geerlings MW Sr, Apostolidis C, Molinet R, Geerlings MW Jr, Gansow OA, Scheinberg DA. Nikula TK, et al. Among authors: mcdevitt mr. J Nucl Med. 1999 Jan;40(1):166-76. J Nucl Med. 1999. PMID: 9935073 Free article.

4

An 225Ac/213Bi generator system for therapeutic clinical applications: construction and operation.

McDevitt MR, Finn RD, Sgouros G, Ma D, Scheinberg DA. McDevitt MR, et al. Appl Radiat Isot. 1999 May;50(5):895-904. doi: 10.1016/s0969-8043(98)00151-1. Appl Radiat Isot. 1999. PMID: 10214708

5

Preparation of alpha-emitting 213Bi-labeled antibody constructs for clinical use.

McDevitt MR, Finn RD, Ma D, Larson SM, Scheinberg DA. McDevitt MR, et al. J Nucl Med. 1999 Oct;40(10):1722-7. J Nucl Med. 1999. PMID: 10520715 Free article.

6

Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemia.

Sgouros G, Ballangrud AM, Jurcic JG, McDevitt MR, Humm JL, Erdi YE, Mehta BM, Finn RD, Larson SM, Scheinberg DA. Sgouros G, et al. Among authors: mcdevitt mr. J Nucl Med. 1999 Nov;40(11):1935-46. J Nucl Med. 1999. PMID: 10565792 Free article. Clinical Trial.

7

An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer.

McDevitt MR, Barendswaard E, Ma D, Lai L, Curcio MJ, Sgouros G, Ballangrud AM, Yang WH, Finn RD, Pellegrini V, Geerlings MW Jr, Lee M, Brechbiel MW, Bander NH, Cordon-Cardo C, Scheinberg DA. McDevitt MR, et al. Cancer Res. 2000 Nov 1;60(21):6095-100. Cancer Res. 2000. PMID: 11085533

8

Response of LNCaP spheroids after treatment with an alpha-particle emitter (213Bi)-labeled anti-prostate-specific membrane antigen antibody (J591).

Ballangrud AM, Yang WH, Charlton DE, McDevitt MR, Hamacher KA, Panageas KS, Ma D, Bander NH, Scheinberg DA, Sgouros G. Ballangrud AM, et al. Among authors: mcdevitt mr. Cancer Res. 2001 Mar 1;61(5):2008-14. Cancer Res. 2001. PMID: 11280760

9

Rapid preparation of short-lived alpha particle emitting radioimmunopharmaceuticals.

Ma D, McDevitt MR, Finn RD, Scheinberg DA. Ma D, et al. Among authors: mcdevitt mr. Appl Radiat Isot. 2001 Oct;55(4):463-70. doi: 10.1016/s0969-8043(01)00048-3. Appl Radiat Isot. 2001. PMID: 11545498

10

Breakthrough of 225Ac and its radionuclide daughters from an 225Ac/213Bi generator: development of new methods, quantitative characterization, and implications for clinical use.

Ma D, McDevitt MR, Finn RD, Scheinberg DA. Ma D, et al. Among authors: mcdevitt mr. Appl Radiat Isot. 2001 Nov;55(5):667-78. doi: 10.1016/s0969-8043(01)00062-8. Appl Radiat Isot. 2001. PMID: 11573800

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

89 results

Search Page

Filters